Synthetic 'Upgrade' for Fruit Fly's DNA
By Linda Geddes,
New Scientist
| 08. 13. 2012
The genetic code of the fruit fly Drosophila has been hacked into, allowing it to make proteins with properties that don't exist in the natural world. The advance could ultimately lead to the creation of new or "improved" life forms in the burgeoning field of synthetic biology.
The four letters of the genetic code, A, C, T and G, are read in triplets, called codons, by the cell's protein-making machinery. Each codon gives an instruction for the type of amino acid that gets added next in a protein chain, or tells the machinery to stop.
Jason Chin at the Medical Research Council Laboratory of Molecular Biology in Cambridge, UK, and colleagues previously showed that it was possible to reassign one of these stop codons to incorporate an "unnatural" amino acid instead, and last year they engineered nematode worms to manufacture such proteins.
Complex proposition
However, fruit flies are a much more complex proposition. "They contain significantly more neurons; they can learn; they have all sorts of complicated behaviours," says Chin. "Many of the things we've discovered in biology have actually...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...